JP2004505090A - ピロロ[2,1−b][1,3]ベンゾチアゼピンおよび抗精神病活性を有する薬剤の調製のためのその使用 - Google Patents
ピロロ[2,1−b][1,3]ベンゾチアゼピンおよび抗精神病活性を有する薬剤の調製のためのその使用 Download PDFInfo
- Publication number
- JP2004505090A JP2004505090A JP2002515904A JP2002515904A JP2004505090A JP 2004505090 A JP2004505090 A JP 2004505090A JP 2002515904 A JP2002515904 A JP 2002515904A JP 2002515904 A JP2002515904 A JP 2002515904A JP 2004505090 A JP2004505090 A JP 2004505090A
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- preparation
- compound
- pyrrolo
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 230000000561 anti-psychotic effect Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- YAXACFRTWXKESQ-UHFFFAOYSA-N pyrrolo[2,1-b][1,3]benzothiazepine Chemical class C1=CC2=CC=CC=C2SC2=CC=CN21 YAXACFRTWXKESQ-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 73
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 16
- 230000003291 dopaminomimetic effect Effects 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 15
- 201000000980 schizophrenia Diseases 0.000 claims description 9
- -1 1-imidazolyl Chemical group 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 230000037361 pathway Effects 0.000 claims description 7
- JFLBTRDHDHTNGX-UHFFFAOYSA-N 6-(4-methylpiperazin-1-yl)pyrrolo[2,1-b][1,3]benzothiazepine Chemical compound C1CN(C)CCN1C(C1=CC=CC=C1S1)=CN2C1=CC=C2 JFLBTRDHDHTNGX-UHFFFAOYSA-N 0.000 claims description 6
- 239000003693 atypical antipsychotic agent Substances 0.000 claims description 6
- 229940127236 atypical antipsychotics Drugs 0.000 claims description 6
- RLPMXJWKLTTXDD-UHFFFAOYSA-N 3-methyl-6-(4-methylpiperazin-1-yl)pyrrolo[2,1-b][1,3]benzothiazepine Chemical compound C1CN(C)CCN1C(C1=CC=CC=C1S1)=CN2C1=CC=C2C RLPMXJWKLTTXDD-UHFFFAOYSA-N 0.000 claims description 5
- 208000028017 Psychotic disease Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000004547 Hallucinations Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- HJNMOCAMMZEOBF-UHFFFAOYSA-N 8-chloro-6-(4-methylpiperazin-1-yl)pyrrolo[2,1-b][1,3]benzothiazepine Chemical compound C1CN(C)CCN1C(C1=CC(Cl)=CC=C1S1)=CN2C1=CC=C2 HJNMOCAMMZEOBF-UHFFFAOYSA-N 0.000 claims description 2
- 206010041243 Social avoidant behaviour Diseases 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 208000028683 bipolar I disease Diseases 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical group OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- RZQBDIZIQNASEL-UHFFFAOYSA-N 1,3-benzothiazepine Chemical compound S1C=NC=CC2=CC=CC=C12 RZQBDIZIQNASEL-UHFFFAOYSA-N 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 125000005265 dialkylamine group Chemical group 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 102000005962 receptors Human genes 0.000 description 33
- 108020003175 receptors Proteins 0.000 description 33
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 22
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- 239000000164 antipsychotic agent Substances 0.000 description 12
- 238000000921 elemental analysis Methods 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 229940005529 antipsychotics Drugs 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 8
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical group CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 229960003878 haloperidol Drugs 0.000 description 7
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 5
- 229960004170 clozapine Drugs 0.000 description 5
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000009871 nonspecific binding Effects 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical group C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 5
- ZWZRVLJEYRUNHW-UHFFFAOYSA-N 8-fluoro-6-(4-methylpiperazin-1-yl)pyrrolo[2,1-b][1,3]benzothiazepine Chemical compound C1CN(C)CCN1C(C1=CC(F)=CC=C1S1)=CN2C1=CC=C2 ZWZRVLJEYRUNHW-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000003176 neuroleptic agent Substances 0.000 description 4
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 4
- 229960005017 olanzapine Drugs 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 3
- 102000015554 Dopamine receptor Human genes 0.000 description 3
- 108050004812 Dopamine receptor Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 3
- 229960001076 chlorpromazine Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 239000002287 radioligand Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 230000000862 serotonergic effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- ABCRKPVZDDXKEX-UHFFFAOYSA-N 6-(4-methylpiperazin-1-yl)-3-(propan-2-yloxymethyl)pyrrolo[2,1-b][1,3]benzothiazepine Chemical compound C=1N2C(COC(C)C)=CC=C2SC2=CC=CC=C2C=1N1CCN(C)CC1 ABCRKPVZDDXKEX-UHFFFAOYSA-N 0.000 description 2
- AMECFCFFHHGFQV-UHFFFAOYSA-N 6-(4-methylpiperazin-1-yl)pyrrolo[2,1-b][1,3]benzothiazepine-3,5-dicarbaldehyde Chemical compound C1CN(C)CCN1C1=C(C=O)N2C(C=O)=CC=C2SC2=CC=CC=C12 AMECFCFFHHGFQV-UHFFFAOYSA-N 0.000 description 2
- BNUHYEGPJNDGQR-UHFFFAOYSA-N 6-(4-methylpiperazin-1-yl)pyrrolo[2,1-b][1,3]benzothiazepine-3-carbaldehyde Chemical compound C1CN(C)CCN1C1=CN2C(C=O)=CC=C2SC2=CC=CC=C12 BNUHYEGPJNDGQR-UHFFFAOYSA-N 0.000 description 2
- KDGNDCXRBZFWQK-UHFFFAOYSA-N 8-bromo-5h-pyrrolo[2,1-b][1,3]benzothiazepin-6-one Chemical compound C1C(=O)C2=CC(Br)=CC=C2SC2=CC=CN21 KDGNDCXRBZFWQK-UHFFFAOYSA-N 0.000 description 2
- CSNIQAUZCRKZQP-UHFFFAOYSA-N 8-bromo-6-(4-ethylpiperazin-1-yl)pyrrolo[2,1-b][1,3]benzothiazepine Chemical compound C1CN(CC)CCN1C(C1=CC(Br)=CC=C1S1)=CN2C1=CC=C2 CSNIQAUZCRKZQP-UHFFFAOYSA-N 0.000 description 2
- JDXIFXASVQAKDO-UHFFFAOYSA-N 8-bromo-6-(4-methylpiperazin-1-yl)pyrrolo[2,1-b][1,3]benzothiazepine Chemical compound C1CN(C)CCN1C(C1=CC(Br)=CC=C1S1)=CN2C1=CC=C2 JDXIFXASVQAKDO-UHFFFAOYSA-N 0.000 description 2
- YNIOUXFDFWMEMT-UHFFFAOYSA-N 8-chloro-5h-pyrrolo[2,1-b][1,3]benzothiazepin-6-one Chemical compound C1C(=O)C2=CC(Cl)=CC=C2SC2=CC=CN21 YNIOUXFDFWMEMT-UHFFFAOYSA-N 0.000 description 2
- HVURSJOBNONOOL-UHFFFAOYSA-N 8-chloro-6-(4-ethylpiperazin-1-yl)pyrrolo[2,1-b][1,3]benzothiazepine Chemical compound C1CN(CC)CCN1C(C1=CC(Cl)=CC=C1S1)=CN2C1=CC=C2 HVURSJOBNONOOL-UHFFFAOYSA-N 0.000 description 2
- FALNVJOEUBWZEU-UHFFFAOYSA-N 8-chloro-6-(4-methyl-1,4-diazepan-1-yl)pyrrolo[2,1-b][1,3]benzothiazepine Chemical compound C1CN(C)CCCN1C(C1=CC(Cl)=CC=C1S1)=CN2C1=CC=C2 FALNVJOEUBWZEU-UHFFFAOYSA-N 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000027776 Extrapyramidal disease Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010018687 Granulocytopenia Diseases 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GACYTTWULSRQOC-UHFFFAOYSA-N [6-(4-methylpiperazin-1-yl)pyrrolo[2,1-b][1,3]benzothiazepin-3-yl]methanol Chemical compound C1CN(C)CCN1C(C1=CC=CC=C1S1)=CN2C1=CC=C2CO GACYTTWULSRQOC-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000000742 histaminergic effect Effects 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 229960000582 mepyramine Drugs 0.000 description 2
- JIKUXBYRTXDNIY-UHFFFAOYSA-N n-methyl-n-phenylformamide Chemical compound O=CN(C)C1=CC=CC=C1 JIKUXBYRTXDNIY-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960001289 prazosin Drugs 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
- FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 description 1
- FXHRAKUEZPSMLJ-UHFFFAOYSA-N 1-methyl-1,4-diazepane Chemical compound CN1CCCNCC1 FXHRAKUEZPSMLJ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- BYHKGNWKJMGHGE-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-1,3-benzothiazole Chemical compound C1=C2OCOC2=CC(CN2CCN(CC2)C=2SC3=CC=CC=C3N=2)=C1 BYHKGNWKJMGHGE-UHFFFAOYSA-N 0.000 description 1
- JXEPXKVGKPFBAB-UHFFFAOYSA-N 2h-pyrrolo[2,3-i][1,2]benzothiazepine Chemical group C1=CC2=CC=CNSC2=C2C1=NC=C2 JXEPXKVGKPFBAB-UHFFFAOYSA-N 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- RHVFIPIYPZRQNT-UHFFFAOYSA-N 5h-pyrrolo[2,1-b][1,3]benzothiazepin-6-one Chemical compound O=C1CN2C=CC=C2SC2=CC=CC=C12 RHVFIPIYPZRQNT-UHFFFAOYSA-N 0.000 description 1
- JIUHAPRBMUPNAB-UHFFFAOYSA-N 8-fluoro-5h-pyrrolo[2,1-b][1,3]benzothiazepin-6-one Chemical compound C1C(=O)C2=CC(F)=CC=C2SC2=CC=CN21 JIUHAPRBMUPNAB-UHFFFAOYSA-N 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- GOTMKOSCLKVOGG-UHFFFAOYSA-N SCH 23390 Chemical compound C1N(C)CCC2=CC(Cl)=C(O)C=C2C1C1=CC=CC=C1 GOTMKOSCLKVOGG-UHFFFAOYSA-N 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002870 effect on schizophrenia Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001186 methysergide Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2000RM000432A IT1317884B1 (it) | 2000-08-01 | 2000-08-01 | Pirrolo (2,1-b)(1,3)benzotiazepine e loro uso per la preparazione dimedicamenti ad attivita' antipsicotica classica. |
PCT/IT2001/000406 WO2002010175A1 (en) | 2000-08-01 | 2001-07-26 | PYRROLO[2,1-b][1,3]BENZOTHIAZEPINES AND THEIR USE FOR THE PREPARATION OF MEDICAMENTS WITH ANTIPSYCHOTIC ACTIVITY |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004505090A true JP2004505090A (ja) | 2004-02-19 |
JP2004505090A5 JP2004505090A5 (de) | 2008-09-11 |
Family
ID=11454865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002515904A Withdrawn JP2004505090A (ja) | 2000-08-01 | 2001-07-26 | ピロロ[2,1−b][1,3]ベンゾチアゼピンおよび抗精神病活性を有する薬剤の調製のためのその使用 |
Country Status (20)
Country | Link |
---|---|
US (1) | US6710041B2 (de) |
EP (1) | EP1307463B1 (de) |
JP (1) | JP2004505090A (de) |
KR (1) | KR100826304B1 (de) |
CN (1) | CN1264848C (de) |
AT (1) | ATE287890T1 (de) |
AU (2) | AU8439101A (de) |
BR (1) | BR0112843A (de) |
CA (1) | CA2415475C (de) |
CZ (1) | CZ299340B6 (de) |
DE (1) | DE60108642T2 (de) |
DK (1) | DK1307463T3 (de) |
ES (1) | ES2236291T3 (de) |
HK (1) | HK1059774A1 (de) |
IT (1) | IT1317884B1 (de) |
MX (1) | MXPA03000775A (de) |
PL (1) | PL203096B1 (de) |
PT (1) | PT1307463E (de) |
SK (1) | SK287248B6 (de) |
WO (1) | WO2002010175A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20040178A1 (it) * | 2004-04-07 | 2004-07-07 | Sigma Tau Ind Farmaceuti | Composti ad attivita' antipsicotica atipica. |
ITRM20040222A1 (it) * | 2004-05-07 | 2004-08-07 | Sigma Tau Ind Farmaceuti | Derivati dealchilati di pirrolo[2,1-b]benzotiazepine ad attivita' antipsicotica atipica. |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1301965B1 (it) | 1998-07-28 | 2000-07-20 | Sigma Tau Ind Farmaceuti | Pirrolo (2,1-b)(1,3) benzotiazepine con attivita' antipsicoticaatipica. |
-
2000
- 2000-08-01 IT IT2000RM000432A patent/IT1317884B1/it active
-
2001
- 2001-07-26 WO PCT/IT2001/000406 patent/WO2002010175A1/en active IP Right Grant
- 2001-07-26 JP JP2002515904A patent/JP2004505090A/ja not_active Withdrawn
- 2001-07-26 SK SK130-2003A patent/SK287248B6/sk not_active IP Right Cessation
- 2001-07-26 CA CA2415475A patent/CA2415475C/en not_active Expired - Fee Related
- 2001-07-26 KR KR1020037000934A patent/KR100826304B1/ko not_active IP Right Cessation
- 2001-07-26 US US10/343,627 patent/US6710041B2/en not_active Expired - Fee Related
- 2001-07-26 MX MXPA03000775A patent/MXPA03000775A/es active IP Right Grant
- 2001-07-26 EP EP01963371A patent/EP1307463B1/de not_active Expired - Lifetime
- 2001-07-26 PT PT01963371T patent/PT1307463E/pt unknown
- 2001-07-26 AU AU8439101A patent/AU8439101A/xx active Pending
- 2001-07-26 AU AU2001284391A patent/AU2001284391B2/en not_active Ceased
- 2001-07-26 DK DK01963371T patent/DK1307463T3/da active
- 2001-07-26 AT AT01963371T patent/ATE287890T1/de not_active IP Right Cessation
- 2001-07-26 DE DE60108642T patent/DE60108642T2/de not_active Expired - Lifetime
- 2001-07-26 ES ES01963371T patent/ES2236291T3/es not_active Expired - Lifetime
- 2001-07-26 BR BR0112843-4A patent/BR0112843A/pt not_active Application Discontinuation
- 2001-07-26 PL PL365008A patent/PL203096B1/pl not_active IP Right Cessation
- 2001-07-26 CN CNB018133886A patent/CN1264848C/zh not_active Expired - Fee Related
- 2001-07-26 CZ CZ20030012A patent/CZ299340B6/cs not_active IP Right Cessation
-
2004
- 2004-02-06 HK HK04100773A patent/HK1059774A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
SK287248B6 (sk) | 2010-04-07 |
CN1264848C (zh) | 2006-07-19 |
PT1307463E (pt) | 2005-04-29 |
DK1307463T3 (da) | 2005-05-23 |
KR100826304B1 (ko) | 2008-04-29 |
ITRM20000432A0 (it) | 2000-08-01 |
US6710041B2 (en) | 2004-03-23 |
ATE287890T1 (de) | 2005-02-15 |
HK1059774A1 (en) | 2004-07-16 |
EP1307463A1 (de) | 2003-05-07 |
CA2415475C (en) | 2010-09-28 |
PL203096B1 (pl) | 2009-08-31 |
ITRM20000432A1 (it) | 2002-02-01 |
DE60108642T2 (de) | 2006-06-14 |
AU2001284391B2 (en) | 2006-09-28 |
SK1302003A3 (en) | 2003-05-02 |
CZ200312A3 (cs) | 2003-05-14 |
IT1317884B1 (it) | 2003-07-15 |
CN1444588A (zh) | 2003-09-24 |
DE60108642D1 (de) | 2005-03-03 |
KR20030019598A (ko) | 2003-03-06 |
MXPA03000775A (es) | 2003-10-15 |
BR0112843A (pt) | 2003-04-22 |
ES2236291T3 (es) | 2005-07-16 |
PL365008A1 (en) | 2004-12-27 |
AU8439101A (en) | 2002-02-13 |
WO2002010175A1 (en) | 2002-02-07 |
CZ299340B6 (cs) | 2008-06-25 |
EP1307463B1 (de) | 2005-01-26 |
CA2415475A1 (en) | 2002-02-07 |
US20030186959A1 (en) | 2003-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IE59864B1 (en) | Thiazepine compounds | |
US20170342054A1 (en) | Compounds and methods of use thereof | |
KR20000076190A (ko) | 치환된 4-아릴메틸렌-2-이미노-2,3-디히드로티아졸과 유도체 및 그 제약적 용도 | |
CZ151795A3 (en) | Condensed benzo derivatives, their use and pharmaceutical compositions containing thereof | |
EP1636241A1 (de) | Imidazo[2,1-b]-1,3,4-thiadazolsulfoxide und sulfone | |
TW406083B (en) | Novel piperazine derivatives | |
EP0444924B1 (de) | Kondensierte 7-gliedrige zyklische Verbindungen und diese enthaltende antipsychotische Zubereitung | |
JP2004505090A (ja) | ピロロ[2,1−b][1,3]ベンゾチアゼピンおよび抗精神病活性を有する薬剤の調製のためのその使用 | |
CZ290678B6 (cs) | 3-Substituované 3,4,5,7-tetrahydropyrrolo[3´,4´: 4,5]thieno[2,3-d]pyrimidinové deriváty, způsob jejich přípravy a použití | |
BG63206B1 (bg) | Кондензирани тиазолови производни с афинитет към 5-нт рецептори | |
EP0376633B1 (de) | Benzoxazepinderivate | |
JP2003513095A (ja) | タキキニン受容体アンタゴニストの多形 | |
KR100642730B1 (ko) | 비정형적인 향정신성 작용을 갖는피롤로[2,1-b][1,3]벤조티아제핀 | |
JP2002504104A (ja) | 3−置換ピリド[3’,4’:4,5]チエノ[2,3−d]ピリミジン誘導体、その合成方法および使用 | |
AU2001284391A1 (en) | Pyrrolo[2,1-b][1,3]benzothiazepines and their use for the preparation of medicaments with antipsychotic activity | |
AU762526B2 (en) | Novel type condensed pyridazinone compounds | |
HU225327B1 (en) | Pyrrolo[2,1-b][1,3]benzothiazepines and their use for the preparation of medicaments with antipsychotic activity | |
UA58534C2 (uk) | Похідні 2,3-(1н, 4н)-хіноксаліндіону, фармацевтична комозиція, спосіб лікування, проміжна сполука (варіанти), спосіб одержання сполуки (варіанти) | |
JPH10508309A (ja) | 5−ht2レセプター親和性を有する置換四環状オキサゼピン及びチアゼピン誘導体 | |
WO2023230649A1 (en) | Compounds | |
JP2008542222A (ja) | マレイン酸ベンゾアゼピニウム誘導体の結晶形 | |
JPS63307883A (ja) | 5−置換−10−シアノメチレン−チエノ〔3,4−b〕−ベンゾ−アゼピン | |
JP2002138053A (ja) | 中枢神経系疾患予防・治療剤 | |
CZ2000947A3 (cs) | Substituované chromanové deriváty |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080728 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080728 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20110127 |